Clinical Trials | March 20, 2026
The Clear Lake facility marks Clariant’s first U.S. site dedicated to PEG excipient production
The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
The framework introduces 15 consensus terms and definitions grouped across four core dimensions of skin health
The company announced positive topline data from the Phase 3 ADorable-1 trial
The planned facility, to be built at Samsung’s Bio Campus II, is set to become a launchpad for up to 30 emerging biotech firms
The initiative comes through a collaboration with Asia’s oldest latex condom manufacturer
Subscribe To Our Newsletter & Stay Updated
